Paper Report for: Avogaro_2018_Br.J.Clin.Pharmacol_84_1686
Reference
Title: The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors Avogaro A, Fadini GP Ref: British Journal of Clinical Pharmacology, 84:1686, 2018 : PubMed
Patients with Type 2 diabetes have an excess risk for cardiovascular disease. One of the several approaches, included in the guidelines for the management of Type 2 diabetes, is based on dipeptidyl peptidase 4 (DPP-4; also termed CD26) inhibitors, also called gliptins. Gliptins inhibit the degradation of glucagon-like peptide-1 (GLP-1): this effect is associated with increased circulating insulin-to-glucagon ratio, and a consequent reduction of HbA1c. In addition to incretin hormones, there are several proteins that may be affected by DPP-4 and its inhibition: among these some are relevant for the cardiovascular system homeostasis such as SDF-1alpha and its receptor CXCR4, brain natriuretic peptides, neuropeptide Y and peptide YY. In this review, we will discuss the pathophysiological relevance of gliptin pleiotropism and its translational potential.
        
Related information
Citations formats
Avogaro A, Fadini GP (2018) The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors British Journal of Clinical Pharmacology84: 1686-1695
Avogaro A, Fadini GP (2018) British Journal of Clinical Pharmacology84: 1686-1695